{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:17:34Z","timestamp":1793146654205,"version":"4.5.0"},"reference-count":27,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,2,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Immune-mediated thrombotic thrombocytopenic purpura (iTTP) survivors experience high rates of adverse health sequelae and increased mortality over long-term follow-up. We conducted this multicenter cohort study to evaluate long-term mortality and causes of death in iTTP survivors. Between 2003 and 2020, 222 patients were enrolled in the Ohio State University and Johns Hopkins TTP registries and followed for a median of 4.5 (interquartile range [IQR], 75 0.4-11.5) years. Nine patients died during their first iTTP episode, and 29 patients died during follow-up. Mortality rate was 1.8 times higher than expected from an age-, sex-, and race-adjusted reference population. Cardiovascular disease was a leading primary cause of death (27.6%) tied with relapsed iTTP (27.6%), followed by malignancy (20.7%), infection (13.8%), and other causes (10.3%). Male sex (hazard ratio [HR], 3.74; 95% confidence interval [CI], 1.65-8.48), increasing age (HR, 1.04; 95% CI, 1.01-1.07), and number of iTTP episodes (HR, 1.10; 95% CI, 1.01-1.20) were associated with mortality in a model adjusted for African American race (HR, 0.70; 95% CI, 0.30-1.65), hypertension (HR, 0.47; 95% CI, 0.20-1.08), chronic kidney disease (HR 1.46; 95% CI, 0.65-3.30), and site (HR, 1.46; 95% CI, 0.64\u20133.30). There was a trend toward shorter survival in patients with lower ADAMTS13 activity during remission (P = .078). Our study highlights the need for survivorship care and investigation focused on cardiovascular disease and early mortality in TTP survivors.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020004169","type":"journal-article","created":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T22:57:51Z","timestamp":1630364271000},"page":"1264-1270","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":54,"title":["Cardiovascular disease is a leading cause of mortality among TTP survivors in clinical remission"],"prefix":"10.1182","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0882-6793","authenticated-orcid":false,"given":"Senthil","family":"Sukumar","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Medicine, The Ohio State University College of Medicine, Columbus, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Brodsky","sequence":"additional","affiliation":[{"name":"Department of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Hussain","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7117-1075","authenticated-orcid":false,"given":"Lisa","family":"Yanek","sequence":"additional","affiliation":[{"name":"Division of General Internal Medicine, Department of Medicine, Johns Hopkins Hospital, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8673-4317","authenticated-orcid":false,"given":"Alison","family":"Moliterno","sequence":"additional","affiliation":[{"name":"Department of Medicine,"},{"name":"Division of Hematology, Department of Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Brodsky","sequence":"additional","affiliation":[{"name":"Department of Medicine,"},{"name":"Division of Hematology, Department of Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spero R.","family":"Cataland","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, The Ohio State University College of Medicine, Columbus, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruti","family":"Chaturvedi","sequence":"additional","affiliation":[{"name":"Department of Medicine,"},{"name":"Division of Hematology, Department of Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,2,16]]},"reference":[{"issue":"10","key":"2022021616292543200_B1","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1182\/blood-2017-04-636431","article-title":"Pathophysiology of thrombotic thrombocytopenic purpura","volume":"130","author":"Sadler","year":"2017","journal-title":"Blood."},{"issue":"2","key":"2022021616292543200_B2","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/00005792-196603000-00003","article-title":"Thrombotic Thrombocytopenic Pupura: report of 16 cases and review of the literature","volume":"45","author":"Amorosi","year":"1966","journal-title":"Medicine (Baltimore)."},{"issue":"21","key":"2022021616292543200_B3","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1182\/blood-2016-10-709857","article-title":"Thrombotic thrombocytopenic purpura","volume":"129","author":"Joly","year":"2017","journal-title":"Blood."},{"issue":"6","key":"2022021616292543200_B4","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJM199108083250604","article-title":"Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura","volume":"325","author":"Rock","year":"1991","journal-title":"N Engl J Med."},{"issue":"8","key":"2022021616292543200_B5","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1182\/blood-2009-09-243790","article-title":"Survival and relapse in patients with thrombotic thrombocytopenic purpura","volume":"115","author":"Kremer Hovinga","year":"2010","journal-title":"Blood."},{"issue":"10","key":"2022021616292543200_B6","doi-asserted-by":"crossref","first-page":"E208","DOI":"10.1002\/ajh.24138","article-title":"Increased morbidity during long-term follow-up of survivors of thrombotic thrombocytopenic purpura","volume":"90","author":"Chaturvedi","year":"2015","journal-title":"Am J Hematol."},{"issue":"1","key":"2022021616292543200_B7","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/ajh.21881","article-title":"Evidence of persistent neurologic injury following thrombotic thrombocytopenic purpura","volume":"86","author":"Cataland","year":"2011","journal-title":"Am J Hematol."},{"key":"2022021616292543200_B8","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.thromres.2017.01.003","article-title":"Post-traumatic stress disorder and depression in survivors of thrombotic thrombocytopenic purpura","volume":"151","author":"Chaturvedi","year":"2017","journal-title":"Thromb Res."},{"issue":"12","key":"2022021616292543200_B9","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1182\/blood-2013-04-496752","article-title":"Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura","volume":"122","author":"Deford","year":"2013","journal-title":"Blood."},{"issue":"1","key":"2022021616292543200_B10","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1182\/asheducation-2018.1.548","article-title":"TTP: long-term outcomes following recovery","volume":"2018","author":"George","year":"2018","journal-title":"Hematology (Am Soc Hematol Educ Program)."},{"issue":"13","key":"2022021616292543200_B11","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1182\/blood.2019001056","article-title":"Reduced ADAMTS13 activity during TTP remission is associated with stroke in TTP survivors","volume":"134","author":"Upreti","year":"2019","journal-title":"Blood."},{"issue":"11","key":"2022021616292543200_B12","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1111\/jth.13479","article-title":"Low ADAMTS-13 activity and the risk of coronary heart disease - a prospective cohort study: the Rotterdam Study","volume":"14","author":"Sonneveld","year":"2016","journal-title":"J Thromb Haemost."},{"issue":"1","key":"2022021616292543200_B13","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.atherosclerosis.2009.04.013","article-title":"Lower levels of ADAMTS13 are associated with cardiovascular disease in young patients [published correction appears in Atherosclerosis. 2014;237(1):30]","volume":"207","author":"Bongers","year":"2009","journal-title":"Atherosclerosis."},{"issue":"25","key":"2022021616292543200_B14","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1182\/blood-2015-05-643338","article-title":"Low ADAMTS13 activity is associated with an increased risk of ischemic stroke","volume":"126","author":"Sonneveld","year":"2015","journal-title":"Blood."},{"issue":"12","key":"2022021616292543200_B15","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1161\/ATVBAHA.116.308225","article-title":"Von Willebrand Factor, ADAMTS13, and the Risk of Mortality: The Rotterdam Study","volume":"36","author":"Sonneveld","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol."},{"issue":"5","key":"2022021616292543200_B16","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/j.1365-2141.2008.07107.x","article-title":"Relationship between ADAMTS13 activity in clinical remission and the risk of TTP relapse","volume":"141","author":"Jin","year":"2008","journal-title":"Br J Haematol."},{"key":"2022021616292543200_B17","volume-title":"Underlying Cause of Death 1998-2018.","author":"Centers for Disease Control and Prevention, National Center for Health Statistics"},{"key":"2022021616292543200_B18","volume-title":"Research Methods in Occupational Epidemiology.","author":"Checkoway","year":"1989"},{"issue":"10","key":"2022021616292543200_B19","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1182\/bloodadvances.2017005124","article-title":"Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015","volume":"1","author":"Page","year":"2017","journal-title":"Blood Adv."},{"issue":"24","key":"2022021616292543200_B20","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1182\/blood.2019000748","article-title":"Immune thrombotic thrombocytopenic purpura in older patients: prognosis and long-term survival","volume":"134","author":"Prevel","year":"2019","journal-title":"Blood."},{"issue":"20","key":"2022021616292543200_B21","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1182\/blood-2018-04-840090","article-title":"Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura","volume":"132","author":"Jestin","year":"2018","journal-title":"Blood."},{"issue":"2","key":"2022021616292543200_B22","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3324\/haematol.11739","article-title":"ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission","volume":"93","author":"Peyvandi","year":"2008","journal-title":"Haematologica."},{"issue":"7","key":"2022021616292543200_B23","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1182\/blood-2011-03-341131","article-title":"A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura","volume":"118","author":"Scully","year":"2011","journal-title":"Blood."},{"issue":"14","key":"2022021616292543200_B24","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1182\/blood.2020009150","article-title":"Redefining outcomes in immune TTP: an international working group consensus report","volume":"137","author":"Cuker","year":"2021","journal-title":"Blood."},{"issue":"4","key":"2022021616292543200_B25","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.hoc.2007.06.003","article-title":"Thrombotic thrombocytopenic purpura: a thrombotic disorder caused by ADAMTS13 deficiency","volume":"21","author":"Tsai","year":"2007","journal-title":"Hematol Oncol Clin North Am."},{"issue":"17","key":"2022021616292543200_B26","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1182\/blood-2016-06-724161","article-title":"Clinical importance of ADAMTS13 activity during remission in patients with acquired thrombotic thrombocytopenic purpura","volume":"128","author":"Page","year":"2016","journal-title":"Blood."},{"issue":"24","key":"2022021616292543200_B27","doi-asserted-by":"crossref","first-page":"4177","DOI":"10.1182\/bloodadvances.2019000939","article-title":"Longitudinal assessments of plasma ADAMTS13 biomarkers predict recurrence of immune thrombotic thrombocytopenic purpura","volume":"3","author":"Sui","year":"2019","journal-title":"Blood Adv."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/4\/1264\/1871780\/advancesadv2020004169.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/4\/1264\/1871780\/advancesadv2020004169.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T16:29:56Z","timestamp":1645028996000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/4\/1264\/476716\/Cardiovascular-disease-is-a-leading-cause-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,16]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,2,22]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020004169","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,16]]}}}